Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...

Hepatic Drug Clearance: Effect of Protein Binding

Hepatic Drug Clearance: Effect of Protein Binding

Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...

Antihypertensive Drugs: Types of β-Blockers

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2014

Same author

Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2012

Same author

Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients.

Alimentary pharmacology & therapeutics·2012

Same author

Recurrent primary biliary cirrhosis after liver transplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2010

Same author

Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2009

Same author

Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2008

Same journal

GLP-1 Receptor Agonists and Hepatic Encephalopathy in Cirrhosis: A Protective Signal Requiring Cancer and Nutritional Phenotyping.

Journal of clinical gastroenterology·2026

Same journal

Endoscopic Incisional Therapy for Benign Esophageal Strictures: A Systematic Review and Meta-Analysis.

Journal of clinical gastroenterology·2026

Same journal

International Consensus Statements on the Use of Topical Endoscopic Hemostatic Powders in the Treatment of Acute Gastrointestinal Bleeding.

Journal of clinical gastroenterology·2026

Same journal

Do Risk Factors for Reflux Symptoms After Peroral Endoscopic Myotomy Necessarily Increase the Occurrence of Postoperative Gastroesophageal Reflux?

Journal of clinical gastroenterology·2026

Same journal

Subgroup Stratification by Regimen, Geography, and Population Is Necessary to Validate Nitazoxanide-based Helicobacter pylori Eradication Therapy.

Journal of clinical gastroenterology·2026

Same journal

The Impact of Glucagon-Like Peptide 1 Receptor Agonists Versus Diabetes Mellitus on Endoscopic Procedures: A Case-Control Study From a Large Tertiary Care Health System.

Journal of clinical gastroenterology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 7, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Does propranolol precipitate hepatic encephalopathy?

Journal of Clinical Gastroenterology

|February 1, 1986

Summary

This summary is machine-generated.

Propranolol use in a patient with primary biliary cirrhosis precipitated hepatic coma, which resolved upon drug discontinuation. This suggests beta blockers may induce hepatic encephalopathy, even without gastrointestinal bleeding.

More Related Videos

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

Related Experiment Videos

Last Updated: Jan 7, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

Area of Science:

Hepatology
Pharmacology
Neurology

Background:

Primary biliary cirrhosis (PBC) is a chronic liver disease.
Hepatic coma (encephalopathy) is a severe complication of liver dysfunction.
Beta-blockers, like propranolol, are commonly used for cardiovascular conditions.

Observation:

A 52-year-old woman with PBC developed hepatic coma.
The patient had no prior history of hepatic coma.
The coma emerged during treatment with propranolol.

Findings:

Hepatic coma resolved after discontinuing propranolol.
Gastrointestinal bleeding occurred later but did not trigger hepatic coma.
This temporal relationship suggests a potential link between propranolol and hepatic encephalopathy.

Implications:

Beta-blocker therapy may precipitate hepatic encephalopathy in susceptible patients.
Further investigation is warranted to understand the mechanism of beta-blocker-induced hepatic encephalopathy.
Clinicians should consider beta-blockers as a potential factor in unexplained hepatic encephalopathy.